No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

However, Pfizer's revenue guidance for 2025 doesn't look particularly exciting. The company expects its top line to come in ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

The Schwab U.S. Dividend Equity ETF offers automatic diversification, income, and growth. Read what makes SCHD a solid ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance.

West Virginia Attorney General (AG) Patrick Morrisey announced a total $17 million settlement agreement with pharmaceutical companies, Pfizer and Ranbaxy after more than a decade of litigation ...

Some six and a half years since its debut, Servier’s U.S. arm has made good on its oncology growth ambitions while managing to stay true to its patient-centric ethos along the way. | Some six and a ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Arvinas, Inc, announced that its chief commercial officer, John Northcott, is stepping down as of mid-January. 1 While the ...

Take a look at three predictions for the year ahead for pharma executives considering AI implementation and adoption. For AI to live up to its potential, pharma executives need to not simply invest in ...